tylophorinidine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
*Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, RK; Narasimha Rao, K; Venkatachalam, SR | 1 |
1 other study(ies) available for tylophorinidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine.
Topics: Adolescent; Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thymidylate Synthase | 1998 |